The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / PAD4 Antibodies May Help Predict Treatment Response in Rheumatoid Arthritis

PAD4 Antibodies May Help Predict Treatment Response in Rheumatoid Arthritis

January 17, 2020 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Hybrid Medical Animation / Science Source

Hybrid Medical Animation / Science Source

A study published in Arthritis & Rheumatology highlights how the presence of autoantibodies to peptidylarginine deiminase (PAD) may eventually be used to influence treatment decisions in the management of rheumatoid arthritis (RA), sharpening our understanding of disease subtypes.1 Although follow-up prospective studies are needed, these findings underline some intriguing areas for future investigations in immunobiology.

You Might Also Like
  • Heart Rate Variability to Predict Treatment Response in Patients with RA
  • How Autoimmune & Non-Autoimmune Family Conditions Predict Rheumatoid Arthritis
  • PAD2 & PAD4 Modulate Immune Response in TLR-7-Dependent Lupus
Explore This Issue
January 2020
Also By This Author
  • Measles Is Back. How Does This Affect Patients with Rheumatic Disease?

PAD Background

The PADs are a family of five related isozymes that catalyze the post-translational citrullination of histones, fibrinogen and other proteins. Erika Darrah, PhD, assistant professor of medicine in the division of rheumatology at Johns Hopkins School of Medicine, Baltimore, is first author of the recent Arthritis & Rheumatology paper, “Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies with Favorable Response to Treatment Escalation in Rheumatoid Arthritis.” She explains that PAD2 and PAD4 are both expressed at relatively high levels in the joints of RA patients, and they seem to be the isozymes most relevant to the disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Darrah notes both are produced by inflammatory cells, particularly white blood cells. She adds, “PAD4 is pretty much restricted to those cell types, but PAD2 is expressed at many sites all over the body.”2

This process of extracellular citrullination sometimes leads to multiple isotypes of autoantibodies to citrullinated antigens, termed anti-citrullinated protein antibodies (ACPAs, which are detected via the cyclic citrullinated peptide [CCP] assay). Although citrullination seems to play an important role in many inflammatory processes, the presence of ACPAs is highly specific for RA. ACPAs also indicate a more severe disease course is likely and more aggressive management may be required.3

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Polyclonal antibodies can also develop to the different PAD isoforms themselves, e.g., PAD4 autoantibodies. “PAD4 antibodies are strongly associated with ACPAs and tend to be found in a subset of patients with ACPAs,” Dr. Darrah explains. “If we look just within the CCP-positive individuals, it’s a little less than 50% that will also have antibodies to PAD4.” PAD4 antibodies are found in around 30–35% of the total RA population, making it less sensitive than the standard diagnostic tests for RA: CCP and rheumatoid factor.2

PAD4 antibodies are found at higher rates in patients with more long-standing disease, and they do not appear as often in the preclinical phase of disease compared with a marker such as CCP.2 Several cohort studies have shown PAD4 antibodies are associated with severe erosive disease in patients receiving the standard of care.4-6 However, other evidence suggests that in patients who are also CCP positive, PAD4 autoantibodies are associated with delayed disease onset.7

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Research Reviews, Rheumatoid Arthritis Tagged With: PAD4 autoantibodies, RA Resource CenterIssue: January 2020

You Might Also Like:
  • Heart Rate Variability to Predict Treatment Response in Patients with RA
  • How Autoimmune & Non-Autoimmune Family Conditions Predict Rheumatoid Arthritis
  • PAD2 & PAD4 Modulate Immune Response in TLR-7-Dependent Lupus
  • Researchers Seek to Predict & Prevent Rheumatoid Arthritis

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)